Inhibition of RUNX2 Transcriptional Activity Blocks the Proliferation, Migration and Invasion of Epithelial Ovarian Carcinoma Cells

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Wang, Zhi Qiang ^a,b   Keita, Mamadou ^a,b   Bachvarova, Magdalena ^b   Gobeil, Stephane ^a,b   Morin, Chantale ^b   Plante, Marie ^a,b   Gregoire, Jean ^a,b   Renaud, Marie Claude ^a,b   Sebastianelli, Alexandra ^a,b   Trinh, Xuan Bich ^b,c   Bachvarov, Dimcho ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b Université Laval   (Canada)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR RUNX2;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER INHIBITION; CARCINOGENESIS; CARCINOMA CELL; CELL MIGRATION; CELL PROLIFERATION; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE INDUCTION; GENE REPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; OVARY CARCINOMA; PRIMARY TUMOR; RUNX2 GENE; TRANSCRIPTION REGULATION; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DNA METHYLATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 84885076048     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074384     Document Type: Article

References (83)

1. Siegel R, Ward E, Brawley O, Jemal A, (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
2. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, et al. (2003) Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 189: 1120-1127.
3. Alouini S, (2012) Management of ovarian cancer has changed. Gynecol Oncol 126: 313; author reply 314.
4. Agarwal R, Kaye SB, (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502-516.
5. Jones PA, Baylin SB, (2007) The epigenomics of cancer. Cell 128: 683-692.
6. Balch C, Fang F, Matei DE, Huang TH, Nephew KP, (2009) Minireview: epigenetic changes in ovarian cancer. Endocrinology 150: 4003-4011.
7. Momparler RL, (2003) Cancer epigenetics. Oncogene 22: 6479-6483.
8. Maier S, Dahlstroem C, Haefliger C, Plum A, Piepenbrock C, (2005) Identifying DNA methylation biomarkers of cancer drug response. Am J Pharmacogenomics 5: 223-232.
9. Keita M, Wang ZQ, Pelletier JF, Bachvarova M, Plante M, et al. (2013) Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression. Gynecol Oncol 128: 356-363.
10. Huang X, Peng JW, Speck NA, Bushweller JH, (1999) Solution structure of core binding factor beta and map of the CBF alpha binding site. Nat Struct Biol 6: 624-627.
11. Wang CQ, Jacob B, Nah GS, Osato M, (2010) Runx family genes, niche, and stem cell quiescence. Blood Cells Mol Dis 44: 275-286.
12. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR, (1996) AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84: 321-330.
13. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, et al. (1996) Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A 93: 3444-3449.
14. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, et al. (1997) Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89: 765-771.
15. Levanon D, Bettoun D, Harris-Cerruti C, Woolf E, Negreanu V, et al. (2002) The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons. EMBO J 21: 3454-3463.
16. Fainaru O, Woolf E, Lotem J, Yarmus M, Brenner O, et al. (2004) Runx3 regulates mouse TGF-beta-mediated dendritic cell function and its absence results in airway inflammation. EMBO J 23: 969-979.
17. Blyth K, Cameron ER, Neil JC, (2005) The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 5: 376-387.
18. Subramaniam MM, Chan JY, Yeoh KG, Quek T, Ito K, et al. (2009) Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta 1796: 315-331.
19. Zhang S, Wei L, Zhang A, Zhang L, Yu H, (2009) RUNX3 gene methylation in epithelial ovarian cancer tissues and ovarian cancer cell lines. OMICS 13: 307-311.
20. Lee CW, Chuang LS, Kimura S, Lai SK, Ong CW, et al. (2011) RUNX3 functions as an oncogene in ovarian cancer. Gynecol Oncol 122: 410-417.
21. Scheitz CJ, Tumbar T, (2012) New insights into the role of Runx1 in epithelial stem cell biology and pathology. J Cell Biochem.
22. Wotton S, Stewart M, Blyth K, Vaillant F, Kilbey A, et al. (2002) Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma. Cancer Res 62: 7181-7185.
23. Robinson HM, Broadfield ZJ, Cheung KL, Harewood L, Harris RL, et al. (2003) Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. Leukemia 17: 2249-2250.
24. Planaguma J, Liljestrom M, Alameda F, Butzow R, Virtanen I, et al. (2011) Matrix metalloproteinase-2 and matrix metalloproteinase-9 codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at the invasive front of endometrial and ovarian carcinoma. Hum Pathol 42: 57-67.
25. Keita M, Bachvarova M, Morin C, Plante M, Gregoire J, et al. (2013) The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion. Cell Cycle 12: 972-986.
26. Blyth K, Vaillant F, Jenkins A, McDonald L, Pringle MA, et al. (2010) Runx2 in normal tissues and cancer cells: A developing story. Blood Cells Mol Dis 45: 117-123.
27. Martin JW, Zielenska M, Stein GS, van Wijnen AJ, Squire JA, (2011) The Role of RUNX2 in Osteosarcoma Oncogenesis. Sarcoma 2011: 282745.
28. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, et al. (2005) The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 25: 8581-8591.
29. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, et al. (2010) Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29: 811-821.
30. Niu DF, Kondo T, Nakazawa T, Oishi N, Kawasaki T, et al. (2012) Transcription factor Runx2 is a regulator of epithelial-mesenchymal transition and invasion in thyroid carcinomas. Lab Invest 92: 1181-1190.
31. Kayed H, Jiang X, Keleg S, Jesnowski R, Giese T, et al. (2007) Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer. Br J Cancer 97: 1106-1115.
32. Li W, Xu S, Lin S, Zhao W, (2012) Overexpression of runt-related transcription factor-2 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer. J Biomed Biotechnol 2012: 456534.
33. Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, et al. (2000) Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst 92: 1534-1535.
34. Provencher DM, Lounis H, Champoux L, Tetrault M, Manderson EN, et al. (2000) Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim 36: 357-361.
35. Sasaki H, Sheng Y, Kotsuji F, Tsang BK, (2000) Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 60: 5659-5666.
36. L'Esperance S, Bachvarova M, Tetu B, Mes-Masson AM, Bachvarov D, (2008) Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics 9: 99.
37. Mercier PL, Bachvarova M, Plante M, Gregoire J, Renaud MC, et al. (2011) Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol 5: 438-453.
38. Keita M, Bachvarova M, Morin C, Plante M, Gregoire J, et al. (2013) The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion. Cell Cycle 12.
39. Tetu B, Popa I, Bairati I, L'Esperance S, Bachvarova M, et al. (2008) Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas. Mod Pathol 21: 1002-1010.
40. Sandi MJ, Hamidi T, Malicet C, Cano C, Loncle C, et al. (2011) p8 expression controls pancreatic cancer cell migration, invasion, adhesion, and tumorigenesis. J Cell Physiol 226: 3442-3451.
41. Cano CE, Hamidi T, Sandi MJ, Iovanna JL, (2011) Nupr1: the Swiss-knife of cancer. J Cell Physiol 226: 1439-1443.
42. Kanamori Y, Matsushima M, Minaguchi T, Kobayashi K, Sagae S, et al. (1999) Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res 59: 4225-4227.
43. Zhao H, Yang Z, Wang X, Zhang X, Wang M, et al. (2012) Triptolide inhibits ovarian cancer cell invasion by repression of matrix metalloproteinase 7 and 19 and upregulation of E-cadherin. Exp Mol Med 44: 633-641.
44. Daikoku T, Wang D, Tranguch S, Morrow JD, Orsulic S, et al. (2005) Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res 65: 3735-3744.
45. Purcell DJ, Khalid O, Ou CY, Little GH, Frenkel B, et al. (2012) Recruitment of coregulator G9a by Runx2 for selective enhancement or suppression of transcription. J Cell Biochem 113: 2406-2414.
46. van der Deen M, Akech J, Lapointe D, Gupta S, Young DW, et al. (2012) Genomic promoter occupancy of runt-related transcription factor RUNX2 in Osteosarcoma cells identifies genes involved in cell adhesion and motility. J Biol Chem 287: 4503-4517.
47. Li H, Zhou RJ, Zhang GQ, Xu JP, (2013) Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study. Tumour Biol.
48. Kim DJ, Akiyama TE, Harman FS, Burns AM, Shan W, et al. (2004) Peroxisome proliferator-activated receptor beta (delta)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J Biol Chem 279: 23719-23727.
49. Huang Z, Cheng Y, Chiu PM, Cheung FM, Nicholls JM, et al. (2012) Tumor suppressor Alpha B-crystallin (CRYAB) associates with the cadherin/catenin adherens junction and impairs NPC progression-associated properties. Oncogene 31: 3709-3720.
50. Fridman JS, Rehemtulla A, Hofmann A, Blau HM, Maybaum J, (1998) Expression of Bcl-XS alters cytokinetics and decreases clonogenic survival in K12 rat colon carcinoma cells. Oncogene 17: 2981-2991.
51. Mansour M, Palese P, Zamarin D, (2011) Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J Virol 85: 6015-6023.
52. Hishikawa K, Oemar BS, Tanner FC, Nakaki T, Luscher TF, et al. (1999) Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7. J Biol Chem 274: 37461-37466.
53. Capparelli C, Whitaker-Menezes D, Guido C, Balliet R, Pestell TG, et al. (2012) CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. Cell Cycle 11: 2272-2284.
54. Yang MH, Lin BR, Chang CH, Chen ST, Lin SK, et al. (2012) Connective tissue growth factor modulates oral squamous cell carcinoma invasion by activating a miR-504/FOXP1 signalling. Oncogene 31: 2401-2411.
55. Ofek P, Ben-Meir D, Kariv-Inbal Z, Oren M, Lavi S, (2003) Cell cycle regulation and p53 activation by protein phosphatase 2C alpha. J Biol Chem 278: 14299-14305.
56. Morrow KA, Das S, Metge BJ, Ye K, Mulekar MS, et al. (2011) Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation. J Biol Chem 286: 40376-40385.
57. Li W, Giancotti FG, (2010) Merlin's tumor suppression linked to inhibition of the E3 ubiquitin ligase CRL4 (DCAF1). Cell Cycle 9: 4433-4436.
58. Lecomte C, Andujar P, Renier A, Kheuang L, Abramowski V, et al. (2005) Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma. Cell Cycle 4: 1862-1869.
59. Daikoku T, Tranguch S, Chakrabarty A, Wang D, Khabele D, et al. (2007) Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer. Cancer Res 67: 5285-5292.
60. Madsen CV, Steffensen KD, Olsen DA, Waldstrom M, Sogaard CH, et al. (2012) Serum platelet-derived growth factor and fibroblast growth factor in patients with benign and malignant ovarian tumors. Anticancer Res 32: 3817-3825.
61. Papacleovoulou G, Critchley HO, Hillier SG, Mason JI, (2011) IL1alpha and IL4 signalling in human ovarian surface epithelial cells. J Endocrinol 211: 273-283.
62. Brard L, Lange TS, Robison K, Kim KK, Ara T, et al. (2011) Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines. Gynecol Oncol 123: 370-378.
63. Sundfeldt K, Ivarsson K, Carlsson M, Enerback S, Janson PO, et al. (1999) The expression of CCAAT/enhancer binding protein (C/EBP) in the human ovary in vivo: specific increase in C/EBPbeta during epithelial tumour progression. Br J Cancer 79: 1240-1248.
64. Mann AP, Somasunderam A, Nieves-Alicea R, Li X, Hu A, et al. (2010) Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting. PLoS One 5.
65. Stone B, Schummer M, Paley PJ, Thompson L, Stewart J, et al. (2003) Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. Int J Cancer 104: 73-84.
66. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, et al. (2004) Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10: 3291-3300.
67. Li H, Bitler BG, Vathipadiekal V, Maradeo ME, Slifker M, et al. (2012) ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev Res (Phila) 5: 484-491.
68. Bock AJ, Stavnes HT, Kempf T, Trope CG, Berner A, et al. (2010) Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions. Int J Gynecol Cancer 20: 1448-1455.
69. Agarwal A, Tressel SL, Kaimal R, Balla M, Lam FH, et al. (2010) Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy. Cancer Res 70: 5880-5890.
70. Hantke B, Harbeck N, Schmalfeldt B, Claes I, Hiller O, et al. (2003) Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients. Biol Chem 384: 1247-1251.
71. Alper O, Bergmann-Leitner ES, Abrams S, Cho-Chung YS, (2001) Apoptosis, growth arrest and suppression of invasiveness by CRE-decoy oligonucleotide in ovarian cancer cells: protein kinase A downregulation and cytoplasmic export of CRE-binding proteins. Mol Cell Biochem 218: 55-63.
72. Casaburi I, Avena P, Lanzino M, Sisci D, Giordano F, et al. (2012) Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances cyclin D1 expression and promotes human endometrial cancer cell proliferation. Cell Cycle 11: 2699-2710.
73. Kinjo K, Sandoval S, Sakamoto KM, Shankar DB, (2005) The role of CREB as a proto-oncogene in hematopoiesis. Cell Cycle 4: 1134-1135.
74. Duprez E, (2004) A new role for C/EBPbeta in acute promyelocytic leukemia. Cell Cycle 3: 389-390.
75. Tamura K, Hua B, Adachi S, Guney I, Kawauchi J, et al. (2005) Stress response gene ATF3 is a target of c-myc in serum-induced cell proliferation. EMBO J 24: 2590-2601.
76. Lehtinen L, Ketola K, Makela R, Mpindi JP, Viitala M, et al. (2013) High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion. Oncotarget 4: 48-63.
77. Taraboletti G, Rusnati M, Ragona L, Colombo G, (2010) Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget 1: 662-673.
78. Karnezis T, Shayan R, Fox S, Achen MG, Stacker SA, (2012) The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway. Oncotarget 3: 893-906.
79. Yamaoka T, Fujimoto M, Ogawa F, Yoshizaki A, Bae SJ, et al. (2011) The roles of P- and E-selectins and P-selectin glycoprotein ligand-1 in primary and metastatic mouse melanomas. J Dermatol Sci 64: 99-107.
80. Okada-Ban M, Moens G, Thiery JP, Jouanneau J, (1999) Nuclear 24 kD fibroblast growth factor (FGF)-2 confers metastatic properties on rat bladder carcinoma cells. Oncogene 18: 6719-6724.
81. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H, (2001) Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 12: 53-72.
82. Yan C, Boyd DD, (2006) ATF3 regulates the stability of p53: a link to cancer. Cell Cycle 5: 926-929.
83. Sternlicht MD, Werb Z, (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17: 463-516.